BioTime, Inc. (NYSE Amex: BTX) announced today that David Warshawsky, Ph.D., CEO of BioTime’s subsidiary LifeMap Sciences, Inc. will provide and update on product development at an investor meeting in New York City today. Dr. Warshawsky will describe the origins of XenneX, a company that LifeMap has agreed to acquire, and the business strategy that led to its rapid rise to profitability. He will describe the GeneCards ® database ( www.genecards.com) which is used as a research tool world-wide in academia, research hospitals, patent offices, and leading biotech and pharma companies. He will report that GeneCards enjoys more than 12 million page visits/year by hundreds of thousands of unique users, consistently in top positions for gene search results in Google. Dr. Warshawsky will discuss LifeMap’s work to build an integrated map of the thousands of cell types in human development, beginning with the fertilized egg and ending in the developed human. Combined with genomics information, the database is expected to become a “road atlas” of human biology benefiting medicine and research. In addition, LifeMap is developing its own proprietary technology to effectively analyze data gathered from the data bases for use in the development of cell-based therapies. LifeMap also plans to market a new disease database called “MalaCards,” which has been developed by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel and may be licensed to LifeMap from Yeda Research and Development Company Ltd, the Technology Transfer Company of the Weizmann Institute. In addition to expanding LifeMap’s data base offerings through the acquisition of XenneX, BioTime plans to make LifeMap the principal marketing subsidiary for BioTime research products, including ACTCellerate™ human progenitor cell lines, GMP human embryonic stem (hES) cell lines, hES cell lines carrying inherited genetic diseases, and ESpan™ growth media for progenitor cell lines for non-therapeutic uses. LifeMap will utilize its databases as part of its on-line marketing strategy to reach life sciences researchers at biotech and pharmaceutical companies and at academic institutions and research hospitals worldwide.